4 completed, 2 recruiting, 1 unknown. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 4, Recruiting 2, Unknown 1 |
Follow Lethargy: new trials by email Literature Review of Lethargy trials Research Report on Lethargy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. Lumateperone 42 mg, Risperidone 2 mg - Apathy, Schizophrenia | Phase 3 | Recruiting | Louisiana State University Health Sciences Center Shreveport | 80 | 2024-06-01 | 2024-07-01 |
| In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. Positron Emission Tomography (PET) with [18F]-FDOPA, Positron Emission Tomography (PET) with [18F]-FEOBV, Magnetic Resonnance Imaging (MRI) - Apathy | Phase 3 | Recruiting | University Hospital, Bordeaux | 30 | 2021-04-13 | 2026-06-10 |
| Apathy in Dementia Methylphenidate Trial 2 Methylphenidate, Placebo - Apathy, Alzheimer's Disease | Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 200 | 2016-01-01 | 2023-06-13 |
| Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia Brexpiprazole - Schizophrenia | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 49 | 2013-11-01 | 2016-03-29 |
| Non Motors Aspects in De Novo Parkinson's Disease Rotigotine, Placebo - Parkinson Disease, Apathy | Phase 3 | Unknown | University Hospital, Grenoble | 199 | 2012-06-01 | 2017-10-26 |
| Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia rivastigmine, placebo - Parkinson's Disease, Apathy | Phase 3 | Completed | University Hospital, Lille | 40 | 2009-03-01 | 2012-04-24 |
| Treatment of Apathy in Alzheimer's Disease With Modafinil Modafinil, Placebo - Apathy, Alzheimer's Disease | Phase 3 | Completed | Brown University | 22 | 2005-07-01 | 2011-03-04 |
Alzheimer Disease (2) · Mental Disorders (2) · Parkinson Disease (2) · Psychotic Disorders (2) · Schizophrenia (2) · Caregiver Burden (1) · Stroke (1)
Nervous System Diseases (7) · Neurobehavioral Manifestations (7) · Neurologic Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Brain Diseases (5) · Central Nervous System Diseases (5) · Neurodegenerative Diseases (4) · Basal Ganglia Diseases (2) · Dementia (2) · Mental Disorders (2) · Movement Disorders (2) · Neurocognitive Disorders (2) · Parkinsonian Disorders (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2)
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Aripiprazole (1) · Cholinesterase Inhibitors (1) · Magnetic Resonance Spectroscopy (1) · Methylphenidate (1) · Modafinil (1) · Olanzapine (1) · Quetiapine Fumarate (1) · Risperidone (1) · Rivastigmine (1) · Transdermal Patch (1) · brexpiprazole (1) · fluorodopa F 18 (1) · lumateperone (1) · rotigotine (1)
Brown University (1) · Johns Hopkins Bloomberg School of Public Health (1) · Louisiana State University Health Sciences Center Shreveport (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · University Hospital, Bordeaux (1) · University Hospital, Grenoble (1) · University Hospital, Lille (1)
United States (4) · France (3) · Canada (1)
Anna Castrioto, MD (1) · David Devos, MD, PhD (1) · Jacobo Mintzer, MD (1) · Junichi Hashimoto, PhD (1) · Laura L Frakey, Ph.D. (1) · Shawn McNeil, MD (1)
PMID 22687392, PMID 24218528, PMID 29347996, PMID 34570180, PMID 37066690, PMID 41521126
2008 (1), F32MH075583 (1), R01AG046543 (1)